Pathologic Complete Response May Be Strong Surrogate Endpoint for Breast Cancer Survival

Pathological complete response appeared to be a viable surrogate outcome for EFS and distant RFS, according to long-term efficacy results from the I-SPY2 TRIAL. 

“Many neoadjuvant trials have established a relationship between pathologic complete response and EFS,” said Dr. Douglas Yee, Departments of Medicine and Pharmacology. 

Read More

Share this post

Related News